Molecular imaging of neuroendocrine tumors

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 6, 2008, Pages 739-749

  Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C 5 hydroxytryptophan; 68Ga DOTA octreotide; 8F fuoro l dopamine; Metaiodobenzylguanidine; Neuroendocrine tumors; Nuclear medicine; PET; Somatostatin receptor scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 6 FLUORODOPA F 18; CARBON 5 HYDROXYTRYPTOPHAN C 11; FLUORODEOXYGLUCOSE; GALLIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] GA 68; GALLIUM 68; INDIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] IN 111; INDIUM 111; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; TECHNETIUM 99M; TECHNETIUM ETHYLENEDIAMINE N,N' DIACETIC ACID HYDRAZINONICOTINYL OCTREOTATE TC 99M; UNCLASSIFIED DRUG;

CARCINOID; DRUG HALF LIFE; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NON INVASIVE PROCEDURE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR CELL; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 69949130192     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.6.739     Document Type: Review

References (84)

1. Blasberg RG. Imaging update: new windows, new views. Clin. Cancer Res. 13, 3444-3448 (2007).
2. Kelloff GJ, Krohn KA, Larson SM et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer. Res. 11, 7967-7985 (2005).
3. Mankoff DA, Krohn KA. PET imaging of response and resistance to cancer therapay. In: Drug Resistance In Cancer. Teicher B (Ed.). Humana Press, Edition Totowa, NJ, USA 105-122 (2006).
4. Janson ET, Oberg K. Malignant neuroendocrine tumors. Cancer Chemother. Biol. Response Modif. 20, 463-470 (2002).
5. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro - enteropancreatic endocrine tumors. J. Mol. Med. 76, 413-420 (1998).
6. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1 - sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28, 836-846 (2001).
7. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781-793 (2003).
8. Krenning EP, Bakker WH, Kooij PP et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med. 33, 652-658 (1992).
9. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716-731 (1993).
10. Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann. Intern. Med. 125, 26-34 (1996).
11. Lebtahi R, Cadiot G, Sarda L et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J. Nucl. Med. 38, 853-858 (1997).
12. 111In-DTPA-octreotide in trie same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 40, 762-767 (1999).
13. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur. J. Nucl. Med. Mol. Imaging 32, 724 (2005).
14. Ginj M, Chen J, Walter MA et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res. 11, 1136-1145 (2005).
15. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur. J. Nucl. Med. Mol. Imaging 33, 1123-1133 (2006).
16. 111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J. Nucl. Med. 46, 1561-1569 (2005).
17. 111In - DTPA - octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med. 44, 708-716 (2003).
18. 99mTc-EDDA/ HYNIC-[Tyr3] octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother. Radiopharm. 19, 73-79 (2004).
19. 99mTc-demotate 1: first data in tumour patients-results of a pilot/Phase I study. Eur. J. Nucl. Med. Mol. Imaging 30, 1211-1219 (2003).
20. 177Lu - DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin, Oncol. 23, 2754-2762 (2005).
21. 177Lu-DOTA(0),Tyr(3)] octreotide: which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging 33, 1346-1351 (2006).
22. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging 30, BP140-147 (2003).
23. Schillaci O, Scopinaro F, Angeletti S et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J. Nucl. Med. 37, 1452-1456 (1996).
24. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15, 966-973 (2004).
25. Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin. Endocrinol. (Oxf.) 59, 793-799 (2003).
26. de Herder WW, Kwekkeboom DJ, Valkema R et al. Neuroendocrine tumors and somatostatin: imaging techniques. J. Endocrinol. Invest. 28, 132-136 (2005).
27. Dromain C, de Baere T, Lumbroso J et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol. 23, 70-78 (2005).
28. Termanini B, Gibril F, Reynolds JC et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112, 335-347 (1997).
29. 111In-pentetreotide scintigraphy. J. Nucl. Med. 43, 889-895 (2002).
30. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J. Nucl. Med. 41, 1704-1713 (2000).
31. 111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur. J. Endocrinol. 131, 577-581 (1994).
32. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med. 46(Suppl. 1), 67S-75S (2005).
33. 131I) benzylguanidine in neuroblastoma. AJR Am. J. Roentgenol. 143, 373-374 (1984).
34. Nakajo M, Shapiro B, Copp J et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131] iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J. Nucl. Med. 24, 672-682 (1983).
35. Shapiro B, Copp JE, Sisson JC et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J. Nucl. Med. 26, 576-585 (1985).
36. Kaltsas G, Korbonits M, Heintz E et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab. 86, 895-902 (2001).
37. Ezziddin S, Logvinski T, Yong-Hing C et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 47, 223-233 (2006).
38. 131I-mIBG]. Clin. Endocrinol. (Oxf.) 55, 47-60 (2001).
39. 131I] iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl. Med. Commun. 26, 969-976 (2005).
40. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36, 228-247 (2006).
41. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med. 16, 210-224 (1975).
42. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189, 847-850 (1993).
43. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 238, 405-422 (2006).
44. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J. Nucl. Med. 42, 1S-93S (2001).
45. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J. Nucl. Med. 47, 451-469 (2006).
46. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 52(Suppl. 4), iv23-iv29 (2003).
47. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin. Nucl. Med. 36, 169-181 (2006).
48. Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J. Clin. Oncol. 23, 4577-4580 (2005).
49. 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. AJR Am. J. Roentgenol. 184, 579-587 (2005).
50. Adams S, Baum R, Rink T et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur. J. Nucl. Med. 25, 79-83 (1998).
51. 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J. Surg. 22, 588-592 (1998).
52. Foidart-Willems J, Depas G, Vivegnis D. Positron emission tomography and radio labeled octreotide scintigraphy in carcinoid tumors. Eur. J. Nucl. Med. 22, 635-638 (1995).
53. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J. Nucl. Med. 38, 1382-1383 (1997).
54. Pearse AG. The APUD concept and hormone production. Clin. Endocrinol. Metab. 9, 211-222 (1980)
55. Ahlstrom H, Eriksson B, Bergstrom M et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195, 333-337 (1995).
56. 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 220, 373-380 (2001).
57. 18F-FDOPA PET. J. Nucl. Med. 45, 1161-1167 (2004).
58. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7, 728-734 (2006).
59. Montravers F, Grahek D, Kerrou K et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455-1462 (2006).
60. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64-71 (2001).
61. 18F-DOPA PET/CT and neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 33, 509-513 (2006).
62. Orlefors H, Sundin A, Ahlstrom H et al. Positron emission tomography with 5,-hydroxytryprophan in neuroendocrine tumors. J. Clin. Oncol. 16, 2534-2541 (1998).
63. Orlefors H, Sundin A, Lu L et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33, 60-65 (2006).
64. Brown WD, Oakes TR, Dejesus OT et al. Fluorine-18-fluoro- L-DOPA dosimetry with carbidopa pretreatment. J. Nucl. Med. 39, 1884-1891 (1998).
65. Orlefors H, Sundin A, Garske U et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J. Clin. Endocrinol. Metab. 90, 3392-3400 (2005).
66. Hofmann M, Maecke H, Borner R et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28, 1751-1757 (2001).
67. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5, 42-48 (2003).
68. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol Imaging 33, 460-466 (2006).
69. 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur. J. Nucl. Med. Mol Imaging 33, 506 (2006).
70. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48, 508-518 (2007).
71. Kayani I, Bomanji JB, Groves A et al. Functional imaging of neuroendocrine tumors with combined PET/CT using (68) Ga-DOTATATE(DOTA-DPhe(1),Tyr(3)-octreotate) and (18)F-FDG. Cancer 112, 2447-2455 (2008).
72. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am. 43, 169-187 (2005).
73. Haubner R, Wester HJ, Burkhart F et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336 (2001).
74. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 55, 1233-1238 (2003).
75. Rajendran JG, Schwartz DL, O'Sullivan J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin. Cancer Res. 12, 5435-5441 (2006).
76. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med. 49(Suppl. 2), 129S-148S (2008).
77. Hendrikse NH, de Vries EG, Eriks-Fluks L et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood - brain barrier. Cancer Res. 59, 2411-2416 (1999).
78. Sasongko L, Link JM, Muzi M et al. Imaging P-glycoprotein transport activity at the human blood - brain barrier with positron emission tomography. Clin. Pharmacol. Ther. 77, 503-514 (2005).
79. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol. Clin. North Am. 43, 153-167 (2005).
80. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18) F] FLT for imaging of cellular proliferation in vivo. Nucl. Med. Biol. 27, 143-156 (2000).
81. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J. Nucl. Med. 49(Suppl. 2), 64S-80S (2008).
82. 99mTc annexin V. J. Nucl. Med. 40, 184-191 (1999).
83. 111In)NH2] -exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin. Cancer Res. 13, 3696-3705 (2007).
84. Modlin IM, Latich I, Zikusoka M et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J. Clin. Gastroenterol. 40, 572-582 (2006).